PBYI - Puma Biotechnology Summary, Stock Quote and News

10.82 -0.35 (-3.13%)

After Hours 10.5 (%)

Data as of Sep 22, 2019

Prev. Close 11.17
Price Open 11.12
Volume 5,371,683
Day's Range 10.61 - 11.28
52 Wk Range 8.45 - 48.8
50 Day Moving Avg. 10.49
PE Ratio 0
Shares Outstanding 38.90M
Market Cap 420.87M

Trade PBYI stock with recommended broker Ally Invest. Commissions as low as $3.95.

Analyst Rating View All Ratings

Date	Research Firm	Action	Current	Target
8/09/19	Barclays	Maintains	Underweight	9.0
5/10/19	Citi	Downgrades	BuyNeutral	24.0
5/10/19	Cantor Fitzgerald	Downgrades	OverweightNeutral	20.0

Puma Biotechnology Announces FDA Acceptance Of Supplemental New Drug Application For Neratinib To Treat HER2-Positive Metastatic Breast Cancer Benzinga NewsdeskWed, 11 Sep 2019 08:09:12 -0400
Puma Biotechnology Licensing Partner Pint Pharma Receives Marketing Authorization For NERLYNX For Extended Adjuvant Treatment Of Early Stage Hormone Receptor Positive, HER2-Positive Breast Cancer Benzinga NewsdeskWed, 04 Sep 2019 16:11:03 -0400
Puma Biotech shares are trading higher after the FDA granted Orphan Drug Destination to NERLYNX for the treatment of breast cancer patients with brain metastases. Benzinga NewsdeskTue, 03 Sep 2019 16:25:54 -0400
Puma Biotech Reports FDA Granted Orphan Drug Designation For Co.'s NERLYNX For Treatment Of Breast Cancer Patients With Brain Metastases Benzinga NewsdeskTue, 03 Sep 2019 16:22:01 -0400
Barclays Maintains Underweight on Puma Biotechnology, Lowers Price Target to $9 Vick MeyerFri, 09 Aug 2019 09:00:21 -0400
Puma Biotechnology shares are trading higher after the company reported better-than-expected Q2 EPS and sales results. Benzinga NewsdeskFri, 09 Aug 2019 08:31:35 -0400
Puma Biotechnology shares are trading higher after the company reported better-than-expected Q2 EPS and sales results. Benzinga NewsdeskThu, 08 Aug 2019 16:28:54 -0400
Puma Biotechnology Q2 EPS $(0.97) Beats $(1) Estimate, Sales $53.9M Beat $52.98M Estimate Benzinga_NewsdeskThu, 08 Aug 2019 16:27:35 -0400
Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Fri., July 26, 2019 Benzinga NewsdeskFri, 26 Jul 2019 14:21:52 -0400
Puma Biotech Highlights Its Licensing Partner Knight Therapeutics Received Regulatory Approval From Health Canada Related To Commericalization Of NERLYNX For HER2-Positive Early-Stage Breast Cancer Benzinga NewsdeskTue, 16 Jul 2019 16:37:49 -0400
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Puma Biotechnology Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer Business WireSep 11, 2019
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business WireSep 05, 2019
Puma Biotechnology Licensing Partner Pint Pharma Receives Marketing Authorization for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive, HER2-Positive Breast Cancer Business WireSep 04, 2019
Puma Biotechnology to Present at the H.C. Wainwright 21st Annual Global Investment Conference Business WireSep 03, 2019
FDA Grants Orphan Drug Designation to Puma Biotechnology's NERLYNX® for the Treatment of Breast Cancer Patients with Brain Metastases Business WireSep 03, 2019
Cellulite Treatment Market Projected to Reach $1,438.5 Billion by 2026 PRNewswireAug 12, 2019
Puma Biotechnology Reports Second Quarter 2019 Financial Results Business WireAug 08, 2019
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business WireAug 06, 2019
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business WireJul 25, 2019
Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results Business WireJul 24, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Do Options Traders Know Something About Puma Biotech (PBYI) Stock We Don't? Zacks6 days ago
Roche's New Perjeta Combo Meets Goal in Breast Cancer Study ZacksSep 13, 2019
Puma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance ZacksSep 12, 2019
FDA accepts Puma's application for expanded use of Nerlynx Seeking AlphaSep 11, 2019
Why Is Puma Biotech (PBYI) Up 16.8% Since Last Earnings Report? ZacksSep 07, 2019
Puma Bio's Nerlynx OK'd in Argentina Seeking AlphaSep 04, 2019
SDRL, GEVO among premarket gainers Seeking AlphaSep 04, 2019
Puma Bio up 9% on Orphan Drug tag for Nerlynx for certain breast cancer patients Seeking AlphaSep 03, 2019
RRD, PBYI, KBR and TLRD among notable after hours movers Seeking AlphaAug 30, 2019
LCI, IRS, PAHC and RLJ among after hour movers Seeking AlphaAug 27, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Earnings View Earnings

Q2 2019	EST	Actual	Surprise
EPS:	-1.000	-0.970	0.0300
Rev:	52.98M	53.90M	920.00K

Q3 2019	EST	Actual	Surprise
EPS:	Expected 2019-10-31
Rev:	Expected 2019-10-31

Fastest Market News Application
You'll Hear It First On Pro

Company Profile

Puma Biotechnology is a biotechnology company focused on developing novel therapeutics for the treatment of cancer. Puma licenses the commercial rights to its current drug candidates. The company expects to augment its product pipeline by acquiring, through license or otherwise, additional drug candidates for research and development and potential commercialization. In evaluating potential drug candidates, Puma employs disciplined decision criteria favoring drug candidates that have undergone at least some clinical study.

Visit company website

Brokerage Center

Compare All Online Brokerages

Market Overview

Puma Biotechnology PBYI:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Company Profile

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners

Membership is Free

What are you waiting for? Sign up now!

Free Account Login

Market Overview

Tickers

Articles

Keywords

Puma Biotechnology PBYI:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Company Profile

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners